Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020

NEXT STORY
Press Release Oncology Venture issues 1,893,939 shares to Negma Group LTD and Park Partners GP and thereby all outstanding convertible loan notes are converted
PREV STORY
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates

SEATTLE and SOUTH SAN FRANCISCO, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Immune Design ...

author_avatar
NASDAQ Market News

Aduro Biotech and Dana-Farber Cancer Institute Publish Data Highlighting Immunosuppressive Impact of APRIL in Multiple Myeloma in Leukemia

BERKELEY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today ...

author_avatar
NASDAQ Market News

Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14

RANCHO CORDOVA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or ...

author_avatar
NASDAQ Market News